We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+78.01%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.2B
AUM Growth
-$344M
Cap. Flow
-$568M
Cap. Flow %
-47.21%
Top 10 Hldgs %
59.33%
Holding
55
New
8
Increased
5
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$34M
2
AVBP icon
ArriVent BioPharma
AVBP
+$20M
3
MANE
Veradermics Inc
MANE
+$15.1M
4
FTH
Faeth Therapeutics
FTH
+$14.4M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$9.12M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$211M
2
TERN
Terns Pharmaceuticals
TERN
+$165M
3
COGT icon
Cogent Biosciences
COGT
+$73M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$57.8M
5
ZBIO
Zenas BioPharma
ZBIO
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENGNW icon
51
enGene Therapeutics Warrants
ENGNW
– –
-285,046
Closed -$844K
PALI icon
52
Palisade Bio
PALI
$348M
– –
-2,293,578
Closed -$5.39M
SLN
53
Silence Therapeutics
SLN
$536M
– –
-1,105,454
Closed -$6.72M
VSTM icon
54
Verastem
VSTM
$539M
– –
-1,106,524
Closed -$8.54M
ZBIO
55
Zenas BioPharma
ZBIO
$2.03B
– –
-853,495
Closed -$31M
1 2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vivo Capital held 55 positions worth $1.2B, down 22% from $1.55B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Vivo Capital withdrew a net $568M in Q1 2026, closing 9 positions and reducing 9 holdings. Its most notable exit was Cidara Therapeutics, an estimated $211M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Vivo Capital opened a new position in ArriVent BioPharma worth $20.4M.

  • Vivo Capital's largest Q1 2026 buy was ArriVent BioPharma: 885,916 shares worth $20.4M.
  • Vivo Capital added most to Erasca in Q1 2026, an estimated $34M increase.
  • Vivo Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $165M.
  • Vivo Capital fully exited Cidara Therapeutics in Q1 2026, selling an estimated $211M.
  • Vivo Capital's ten largest holdings make up 59% of its $1.2B portfolio in Q1 2026.
  • Vivo Capital opened 8 new positions and closed 9 in Q1 2026.
  • Vivo Capital's portfolio value fell 22% quarter-over-quarter to $1.2B.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.